What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline.

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...